Fimasartan, new hypertensive agent, receives marketing approval in Korea

Boryung Pharmaceutical Co., one of Korea's largest pharmaceutical companies, announced on September 9 that they received marketing approval from the Korean Food and Drug Administration (KFDA) for fimasartan, their new medication for treatment of hypertension. Fimasartan is one of several drugs affiliated with angiotensin II Receptor Blocker (ARB) with a selective AT1 receptor blockade effect.
...